These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 32436318)

  • 21. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial.
    Momtazmanesh S; Amirimoghaddam-Yazdi Z; Moghaddam HS; Mohammadi MR; Akhondzadeh S
    Psychiatry Clin Neurosci; 2020 Jul; 74(7):398-405. PubMed ID: 32347624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and prediction of clinical high risk of psychosis in Chinese outpatients using two-stage screening.
    Xu L; Wang Y; Cui H; Tang Y; Wang J; Tang X; Zhang B; Wei Y; Zhu Y; Jiang L; Qian Z; Li H; Zhang T; Wang J
    Schizophr Res; 2018 Dec; 202():284-290. PubMed ID: 29929774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial.
    Bolt LK; Amminger GP; Farhall J; McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Allott KA
    Schizophr Res; 2019 Apr; 206():67-74. PubMed ID: 30558978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of sulforaphane on cognitive function in patients with frontal brain damage: study protocol for a randomised controlled trial.
    Liu F; Huang J; Hei G; Wu R; Liu Z
    BMJ Open; 2020 Oct; 10(10):e037543. PubMed ID: 33067279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calculating individualized risk components using a mobile app-based risk calculator for clinical high risk of psychosis: findings from ShangHai At Risk for Psychosis (SHARP) program.
    Zhang T; Xu L; Li H; Woodberry KA; Kline ER; Jiang J; Cui H; Tang Y; Tang X; Wei Y; Hui L; Lu Z; Cao L; Li C; Niznikiewicz MA; Shenton ME; Keshavan MS; Stone WS; Wang J
    Psychol Med; 2021 Mar; 51(4):653-660. PubMed ID: 31839016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis).
    Zhang T; Xu L; Tang X; Wei Y; Hu Q; Hu Y; Cui H; Tang Y; Hui L; Li C; Cao L; Lu Z; Wang J
    Aust N Z J Psychiatry; 2020 Jul; 54(7):696-706. PubMed ID: 32436725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals.
    Zhang T; Wang J; Xu L; Wei Y; Tang X; Hu Y; Cui H; Tang Y; Li C; Ling Z; Wang J
    Eur Arch Psychiatry Clin Neurosci; 2022 Jun; 272(4):591-602. PubMed ID: 34536114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis.
    Seidman LJ; Giuliano AJ; Meyer EC; Addington J; Cadenhead KS; Cannon TD; McGlashan TH; Perkins DO; Tsuang MT; Walker EF; Woods SW; Bearden CE; Christensen BK; Hawkins K; Heaton R; Keefe RS; Heinssen R; Cornblatt BA;
    Arch Gen Psychiatry; 2010 Jun; 67(6):578-88. PubMed ID: 20530007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of sulforaphane for treatment of mild to moderate depression in patients with history of cardiac interventions: A randomized, double-blind, placebo-controlled clinical trial.
    Ghazizadeh-Hashemi F; Bagheri S; Ashraf-Ganjouei A; Moradi K; Shahmansouri N; Mehrpooya M; Noorbala AA; Akhondzadeh S
    Psychiatry Clin Neurosci; 2021 Aug; 75(8):250-255. PubMed ID: 34033171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive dysfunction in a psychotropic medication-naïve, clinical high-risk sample from the ShangHai-At-Risk-for-Psychosis (SHARP) study: Associations with clinical outcomes.
    Cui H; Giuliano AJ; Zhang T; Xu L; Wei Y; Tang Y; Qian Z; Stone LM; Li H; Whitfield-Gabrieli S; Niznikiewicz M; Keshavan MS; Shenton ME; Wang J; Stone WS
    Schizophr Res; 2020 Dec; 226():138-146. PubMed ID: 32694037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Negative symptoms and impaired social functioning predict later psychosis in Latino youth at clinical high risk in the North American prodromal longitudinal studies consortium.
    Alderman T; Addington J; Bearden C; Cannon TD; Cornblatt BA; McGlashan TH; Perkins DO; Seidman LJ; Tsuang MT; Walker EF; Woods SW; Cadenhead KS
    Early Interv Psychiatry; 2015 Dec; 9(6):467-75. PubMed ID: 24576057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of a family history of psychosis for youth at clinical high risk of psychosis.
    Georgopoulos G; Stowkowy J; Liu L; Cadenhead KS; Cannon TD; Cornblatt BA; McGlashan TH; Perkins DO; Seidman LJ; Tsuang MT; Walker EF; Woods SW; Bearden CE; Mathalon DH; Addington J
    Early Interv Psychiatry; 2019 Apr; 13(2):251-256. PubMed ID: 28792113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Course of psychotic symptoms, depression and global functioning in persons at clinical high risk of psychosis: Results of a longitudinal observation study over three years focusing on both converters and non-converters.
    Hengartner MP; Heekeren K; Dvorsky D; Walitza S; Rössler W; Theodoridou A
    Schizophr Res; 2017 Nov; 189():19-26. PubMed ID: 28139360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duration of the psychosis prodrome.
    Powers AR; Addington J; Perkins DO; Bearden CE; Cadenhead KS; Cannon TD; Cornblatt BA; Mathalon DH; Seidman LJ; Tsuang MT; Walker EF; McGlashan TH; Woods SW
    Schizophr Res; 2020 Feb; 216():443-449. PubMed ID: 31806523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
    McGlashan TH; Zipursky RB; Perkins D; Addington J; Miller T; Woods SW; Hawkins KA; Hoffman RE; Preda A; Epstein I; Addington D; Lindborg S; Trzaskoma Q; Tohen M; Breier A
    Am J Psychiatry; 2006 May; 163(5):790-9. PubMed ID: 16648318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.
    Kantrowitz JT; Woods SW; Petkova E; Cornblatt B; Corcoran CM; Chen H; Silipo G; Javitt DC
    Lancet Psychiatry; 2015 May; 2(5):403-412. PubMed ID: 26360284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.